相关实验视频
Updated: Sep 11, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
乌帕达西提尼布用于难以治疗的儿科克朗氏病
N Nedelkopoulou1, S Sharma1, M Khalid1
1Sheffield Children's Hospital, NHS Foundation Trust Sheffield UK.
JPGN reports
|August 15, 2025
概括
乌帕达西提尼布在治疗耐火性儿科克罗恩病方面表现有前途. 这项研究强调了它在两名青少年中的有效性,表明了严重儿科炎性肠病的潜在新治疗选择.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 炎症性肠道疾病研究研究
- 药理疗法 药理疗法 药理疗法
背景情况:
- 儿科发病的炎症性肠病 (IBD) 带来了重大的长期医疗保健挑战.
- 现有的治疗方法,包括抗瘤缩因子-α药物,需要扩大年轻患者的治疗选择.
- 对于upadacitinib,尽管有充满希望的成年人证据,但儿科数据有限.
研究的目的:
- 评估乌帕达西提尼布在患有高度耐火克罗恩病的青少年中的疗效和安全性.
- 为了解决这一新兴治疗剂的儿科数据的稀缺性.
主要方法:
- 关于两名患有严重克罗恩病的青少年患者的病例报告.
- 在对其他疗法不耐药的患者中使用upadacitinib的治疗.
- 包括一个先前进行过亚整体切除术的患者.
主要成果:
- 在青少年患者中,upadacitinib 证明了有效的治疗效果.
- 即使在患有亚整体切除术史的患者中也观察到积极的结果.
结论:
- 乌帕达西提尼布是一种潜在的有效治疗高度耐药的儿科克罗恩病.
- 这一案例系列支持在儿科IBD群体中进一步调查upadacitinib.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Cystic Fibrosis: Management
224
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
224

